ArticleOphthalmology and therapy2022

Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients.

Kenichi Namba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.